Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label, Two-armed Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

NCT03890952 is registered in ClinicalTrials.gov with Ulrik Lassen as lead sponsor.

NCT NCT03890952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03890952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label, Two-armed Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Lead sponsor
Ulrik Lassen
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2018
Completion date
August 1, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult brain tumor